{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070344","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.199695+00:00","generated_at":"2026-05-21T17:54:35.576348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics Q1 net loss $12.7M, cash $15.9M; RT-114 Phase 1 mid-2025","bullets":["Net loss was $12.7M for Q1 2025 ($14.8M in Q1 2024); cash, equivalents and marketable securities fell to $15.9M from $27.6M at year-end.","Preclinical data show RT-114 (oral bispecific GLP-1/GLP-2 agonist) bioequivalent to subcutaneous PG-102 with 111% relative bioavailability.","Preclinical data also demonstrate oral semaglutide via RaniPill (RT-116) comparable to subcutaneous in bioavailability, PK, and weight loss.","Phase 1 clinical trial for RT-114 treating obesity expected to begin mid-2025.","R&D expenses decreased to $6.6M and G&A to $5.6M; contract revenue was $0.2M from evaluation services."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070344","json":"https://secwatch.observer/filing/0000950170-25-070344.json","markdown":"https://secwatch.observer/filing/0000950170-25-070344.md","text":"https://secwatch.observer/filing/0000950170-25-070344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/0000950170-25-070344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/rani-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:54:35.576348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}